SCHEMBL2392818

SCHEMBL2392818

COC(=O)c1ccc(C(=O)Nc2cc3c4c(c2)CCCC4(C)CCC3)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.48
KDM4E B2RXH2 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
RAB9A P51151 5/20 0.46
NPC1 O15118 3/20 0.46
MAPT P10636 2/20 0.46
TP53 P04637 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
LMNA P02545 1/20 0.43
BACE1 P56817 4/20 0.42
P4HTM Q9NXG6 3/20 0.42
BACE2 Q9Y5Z0 2/20 0.39
ROCK2 O75116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11956666 0.93 MAPK1 (0.47) MAPK1KDM4EL3MBTL1SMN1; SMN2RAB9A
SCHEMBL2396649 0.89 SMN1; SMN2 (0.47) MAPK1KDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL2394731 0.86 KDM4E (0.48) MAPK1KDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL11956667 0.86 P4HTM (0.53) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL2394694 0.84 MAPKAPK2 (0.44) MAPK1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL2397298 0.83 MEN1 (0.46) MAPK1KDM4EL3MBTL1SMN1; SMN2RAB9A
SCHEMBL2394759 0.81 MAPK1 (0.49) MAPK1KDM4EL3MBTL1SMN1; SMN2RAB9A
SCHEMBL2394353 0.81 NPC1 (0.50) MAPK1KDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL2394634 0.80 MAPK1 (0.48) MAPK1KDM4EL3MBTL1SMN1; SMN2RAB9A
SCHEMBL2396642 0.77 P4HTM (0.53) SMN1; SMN2RAB9ANPC1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG MAPK1 3796/4885KDM4E 3386/4885L3MBTL1 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.